Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells.

Notably, CD44v6-PNPs still showed a trend toward increased binding to CD44v6 cells, as compared to control conditions, suggesting that both stability of thioether bond and half-antibody targeting ability are preserved during the tested period of time.

also in 53,322 other papers